Aug 2026· Journal of biochemical and molecular toxicology· Vol 40· 0 citations· 64 references
TL;DR
This review retrieved research on the anti‐myocardial fibrotic effects of curcumin and its analogs published in the last decade from English databases, while a small number of references are older.
Abstract
Myocardial fibrosis is a pathological process characterized by the abnormal accumulation of extracellular matrix, forming pathological scars, due to excessive activation of cardiac fibroblasts during injury repair. This process leads to cardiac stiffening, disruption of electrical conduction, and ultimately, cardiac dysfunction. Curcumin effectively reverses myocardial fibrosis by regulating the metabolic network of extracellular matrix synthesis and degradation. Its analogs, through chemical modification to curcumin, retain and even enhance therapeutic activity meanwhile overcoming inherent limitations of natural curcumin. Given the broad therapeutic potential of curcumin and its analogs against myocardial fibrosis, and the fragmented nature of current research in this field, this review retrieved research on the anti‐myocardial fibrotic effects of curcumin and its analogs published in the last decade from English databases, while a small number of references are older. To establish a theoretical basis for advancing the development and application of curcumin and its analogs, this review synthesizes essential information regarding their properties, mechanisms, pharmacological effects, and therapeutic potential.
Abstract Fibrosis, marked by excessive accumulation of extracellular matrix (ECM) components, ultimately leads to dysfunction and failure of multiple organs, yet effective therapeutic options remain scarce. Curcumin (CUR), a naturally occurring polyphenol with diverse biological activities, has emerged as a promising c...
Ling-Ji Deng, Xiao-Qin Liu, Hao-Yue Feng et al.· Drug Design, Development and...· 0 citations
Future directives necessitate rigorous botanical authentication, pharmacokinetic/pharmacodynamic profiling, and adoption of human-relevant models, such as induced pluripotent stem cell-derived cardiomyocytes, to bridge the bench-to-bedside gap.
Tian-Tian Long, Juncheng Ma, Wei-Jun Hu et al.· International Journal of Mol...· 0 citations
This PUF is considered as a potential integrative therapeutic approach for fibrosis-related diseases and for aggressive cancers with fibrosis, and is expected to target both tumour cells and the fibrotic tumour micro-environment, thereby integrating ethnopharmacological knowledge with molecular rationality.
Rithika Thangaraju, N. Kamlesh, M. Shipin et al.· Frontiers in Pharmacology· 0 citations
Fibrosis is the outcome of chronic diseases and manifests as an abnormal repair process in which normal parenchyma is progressively replaced by deposited extracellular matrix. It leads to organ dysfunction and is associated with high morbidity, disability, and mortality, thereby becoming a major public health concern....
Ting Luo, Jia Gao, Qing-Zhi Liang et al.· Frontiers in Pharmacology· 0 citations
Fibrosis, characterized by abnormal deposition of extracellular matrix, is a chronic disease that progressively remodels tissues, leading to organ failure, earning it the moniker the 'silent killer' of organ function. Recently, ferroptosis, a novel form of regulated cell death, has garnered attention in research; its m...
Xin-Cheng Feng, Jue Zhang, Qing-Yuan Ma et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.